An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.

@article{Danese2011AnOS,
  title={An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.},
  author={Mark D Danese and Robert I Griffiths and Michelle Gleeson and Sacha Satram-Hoang and Kevin B. Knopf and Joseph Mikhael and Carolina Reyes},
  journal={Blood},
  year={2011},
  volume={117 13},
  pages={3505-13}
}
The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and to evaluate outcomes in those patients who initiated infused therapy. Patients 66 years of age and older in the Surveillance, Epidemiology, and End Results (SEER) program with a CLL diagnosis were matched to their Medicare Part A and Part B claims for long-term follow-up. Treatment patterns, survival after initiation of infused therapy, and both hematologic and hospitalization outcomes were assessed. There… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Rituximab prescribing information, revised February 2010. http://www.gene

Genentech, Inc
com/gene/products/information/pdf/rituxanprescribing.pdf. Accessed August • 2010

The addition of rituximab to fludarabine and cyclophosphamide improves the overall survival of patients with chronic lymphocytic leukemia

M Hallek, K Fischer, G Fingerle-Rowson
Non - Hodgkin ’ s Lymphomas : NCCN Clinical Practice Guidelines in Oncology v . 1 . • 2010

Immortal time bias in pharmaco-epidemiology.

American journal of epidemiology • 2008

Similar Papers

Loading similar papers…